60 F
New York
Friday, May 7, 2021

Charles River Laboratories [NYSE: CRL] To Purchase Cognate Bioservices For $875

Must read

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Charles River Laboratories International, Inc. [NYSE: CRL] revealed that the company has entered into a contract to purchase Cognate BioServices, Inc. for around $875 million in cash. The transaction is subject to customary closing conditions.  

James C. Cultivate, CEO of CRL, stated, “Cognate BioServices presents a novel chance to venture into a high-development, value-added area of the CDMO market. Moreover, It aids us to improve our capacity to address our customers’ needs in arising regions of scientific advancement.”

He further added,” This purchase will be an outstanding key fit, adding to our thorough set-up of early-phase study. It will aid in producing support solutions and empowering us to accomplish our objective of building up a solitary scientific partner to furnish biopharmaceutical customers. So that we can provide clients with an incorporated solution to aid enhancing their cell and gene treatment programs.”

Cognate is a cell and gene therapy CDMo that offers a variety of cell therapy solutions. The transaction will create CRL as a sole partner for cell and gene treatment. Furthermore, CRL will be able to provide the customers with integrated solutions from basic research through GCMP creation. Cognate has broad experience creating different cell types and advances utilized in cell immunotherapy and immuno-oncology.

More articles

Latest article

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...

R1 RCM [NASDAQ: RCM] Announces Acquisition of VisitPay

R1 RCM Inc. disclosed Tuesday that it has decided to purchase VisitPay. The firm has inked an agreement to buy VisitPay for nearly...

Binance Coin Makes History as its Market Cap Reach $100 Billion

The market capitalization of Binance set new records as the exchange token of Binance and the native asset of Binance Smart Chain (BSC) touched...

Precipio [NASDAQ: PRPO] Roll Out Rapid COVID-19 Antibody test on Amazon Platform

Shares of Precipio, Inc. skyrocketed 40.35% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments...

TechX Ink Deal to Buy Fiat-to-Crypto Merchant Services Gateway XPort Digital

TechX Technologies Inc disclosed Monday that it has bought fiat-to-crypto merchant services gateway XPort digital. The firm has bought a 100% stake in XPort...

Lockheed [NYSE: LMT] Present F-35 Best and Final Offer to Finnish Government

Lockheed Martin Corporation disclosed that it has presented F-35 best and final offer (BAFO) on April 29, 2021, to the Finnish government. It...

Clene [NASDAQ: CLNN] Gets Two Patent Notice of Allowances

Clene Inc. disclosed that Clene Nanomedicine, Inc. U.S. Patent and Trademark Office has provided Notices of Allowance for two significant patent applications. Clene...